HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster

President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear barriers to access to treatments for serious mental illnesses.

By FierceBiotech · Apr 20, 2026 · via FierceBiotech
Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster

Image: FierceBiotech

Tags
policyformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
Roivant’s CEO thinks China is a ‘red herring’
PolicyFierceBiotech ↗
Roivant’s CEO thinks China is a ‘red herring’
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma ex…
Apr 18, 2026
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
PolicyFierceBiotech ↗
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump adm…
Apr 18, 2026
Trump Administration Again Blocks UNFPA Funding Under Kemp-Kasten
PolicyBriefing
Trump Administration Again Blocks UNFPA Funding Under Kemp-Kasten
Using the Kemp-Kasten amendment, the administration withheld $32.5 million in FY2025 UNFPA support and is expe…
Apr 17, 2026